A Biomedical Test to Transform Clinical Care of Septic Patients in Emergency Settings of Hospital
Inventor(s): Umer Hassan, Sophia Lowe, Muhammad Tahir, Paul Peng
Awarded: May 2025
Summary:
Immuno-Dx is a biomedical test for sepsis stratification to be used in emergency departments of the hospitals. Immuno-Dx comprises of two components, Immuno-Sense and Immuno-AI. Immuno-Sense is an on-chip flow cytometry technology that will analyze our sepsis-specific panel of biomarkers from whole blood. While Immuno-AI is a ML model which will take in biomarkers data and Patients’ EHR data to predict, patient disposition, risk assessment and sepsis diagnosis. Value proposition of Immuno-Dx lies inß its ability to provide vital information about patients’ immune response to infections, and to fulfil unmet need for personalized diagnostics of septic patients in emergency department (ED) settings. Lack of immune and treatment response monitoring tools and over prescription of broad-spectrum antibiotics for infected patients with severe symptoms in ED; are major pain points Immuno-Dx will address. Current ED clinical triage process for sepsis suffers from low specificity, enabling not only delay in the appropriate treatment but also contributing to unnecessary/ non-specific resource allocation to the patients.
Market Applications:
- Immuno-Dx is relevant for different customer segments; however, our initial target beach head market is emergency department (ED) hospital setting.
- We found strong interest in utility of Immuno-Dx in ED settings where it can potentially be used to diagnose septic patients with higher accuracy and predict patients’ disposition and risk stratification.
